1366 related articles for article (PubMed ID: 28669112)
1. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.
Naso MF; Tomkowicz B; Perry WL; Strohl WR
BioDrugs; 2017 Aug; 31(4):317-334. PubMed ID: 28669112
[TBL] [Abstract][Full Text] [Related]
2. Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications.
Schön C; Biel M; Michalakis S
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):343-52. PubMed ID: 25615882
[TBL] [Abstract][Full Text] [Related]
3. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
Shi W; Arnold GS; Bartlett JS
Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
[TBL] [Abstract][Full Text] [Related]
4. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.
Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M
Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018
[TBL] [Abstract][Full Text] [Related]
5. Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution.
Grimm D; Büning H
Hum Gene Ther; 2017 Nov; 28(11):1075-1086. PubMed ID: 28835125
[TBL] [Abstract][Full Text] [Related]
6. Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes.
McClements ME; MacLaren RE
Yale J Biol Med; 2017 Dec; 90(4):611-623. PubMed ID: 29259525
[TBL] [Abstract][Full Text] [Related]
7. Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy.
Liu Y; Siriwon N; Rohrs JA; Wang P
Curr Pharm Des; 2015; 21(22):3248-56. PubMed ID: 26027561
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
Salmon F; Grosios K; Petry H
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):53-65. PubMed ID: 24308784
[TBL] [Abstract][Full Text] [Related]
9. AAV as a viral vector for human gene therapy. Generation of recombinant virus.
Rolling F; Samulski RJ
Mol Biotechnol; 1995 Feb; 3(1):9-15. PubMed ID: 7606507
[TBL] [Abstract][Full Text] [Related]
10. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
11. Integration of adeno-associated virus (AAV) and recombinant AAV vectors.
McCarty DM; Young SM; Samulski RJ
Annu Rev Genet; 2004; 38():819-45. PubMed ID: 15568995
[TBL] [Abstract][Full Text] [Related]
12. Viral Vectors for Gene Transfer.
Chen YH; Keiser MS; Davidson BL
Curr Protoc Mouse Biol; 2018 Dec; 8(4):e58. PubMed ID: 30485696
[TBL] [Abstract][Full Text] [Related]
13. Novel Lung Tropic Adeno-Associated Virus Capsids for Therapeutic Gene Delivery.
Carneiro A; Lee H; Lin L; van Haasteren J; Schaffer DV
Hum Gene Ther; 2020 Sep; 31(17-18):996-1009. PubMed ID: 32799685
[TBL] [Abstract][Full Text] [Related]
14. Adeno-associated virus integration: virus versus vector.
Smith RH
Gene Ther; 2008 Jun; 15(11):817-22. PubMed ID: 18401436
[TBL] [Abstract][Full Text] [Related]
15. Strategies to circumvent humoral immunity to adeno-associated viral vectors.
Tse LV; Moller-Tank S; Asokan A
Expert Opin Biol Ther; 2015 Jun; 15(6):845-55. PubMed ID: 25985812
[TBL] [Abstract][Full Text] [Related]
16. Vectrology of adeno-associated viruses (AAV).
Skubis-Zegadło J; Stachurska A; Małecki M
Med Wieku Rozwoj; 2013; 17(3):202-6. PubMed ID: 24296444
[TBL] [Abstract][Full Text] [Related]
17. Cancer gene therapy using adeno-associated virus vectors.
Park K; Kim WJ; Cho YH; Lee YI; Lee H; Jeong S; Cho ES; Chang SI; Moon SK; Kang BS; Kim YJ; Cho SH
Front Biosci; 2008 Jan; 13():2653-9. PubMed ID: 17981740
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus (AAV) vectors in cancer gene therapy.
Santiago-Ortiz JL; Schaffer DV
J Control Release; 2016 Oct; 240():287-301. PubMed ID: 26796040
[TBL] [Abstract][Full Text] [Related]
19. The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
Mays LE; Wilson JM
Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617
[TBL] [Abstract][Full Text] [Related]
20. Immune responses to AAV vectors: overcoming barriers to successful gene therapy.
Mingozzi F; High KA
Blood; 2013 Jul; 122(1):23-36. PubMed ID: 23596044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
